Prevalence of gastroprotective agent (GPA) use in adults with arthritis in the United States

References

• Centers for Disease Control, Prevention. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation – United States, 2007–2009. Morbidity and Mortality Weekly Report 2010;59:1261-5
   PubMedGoogle Scholar
• Altman RD. New guidelines for topical NSAIDs in the osteoarthritis treatment paradigm. Curr Med Res Opin 2010;26:2871-6
   PubMed Web of Science ®Google Scholar
• Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-54
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9
   PubMed Web of Science ®Google Scholar
• Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9
   PubMed Web of Science ®Google Scholar
• Cheetham TC, Levy G, Niu F, et al. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 2009;43:1765-73
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96
   PubMed Web of Science ®Google Scholar
• Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037-46
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
   PubMed Web of Science ®Google Scholar
• Simon LS, Hatoum HT, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996;28:204-10
   PubMedGoogle Scholar
• Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25:373-96
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;preprintCD002296
   Google Scholar
• Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26
   PubMed Web of Science ®Google Scholar
• Pasina L, Nobili A, Tettamanti M, et al. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions. Int J Clin Pharmacol Therapeut 2010;48:735-43
   PubMed Web of Science ®Google Scholar
• Superceanu B, Veldhuyzen van Zanten S, Skedgel C, et al. The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy. Can J Gastroenterol 2010;24:481-8
   PubMed Web of Science ®Google Scholar
• Valkhoff VE, van Soest EM, Sturkenboom MC, et al. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Therapeut 2010;31:1218-28
   PubMed Web of Science ®Google Scholar
• van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Therapeut 2007;26:265-75
   PubMed Web of Science ®Google Scholar
• Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993;28:681-7
   PubMed Web of Science ®Google Scholar
• Dimenas E, Glise H, Hallerback B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046-52
   PubMed Web of Science ®Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008;10:348-54
   PubMed Web of Science ®Google Scholar
• Glise H, Hallerback B, Johansson B. Quality of Life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl 1995;208:133-5
   PubMedGoogle Scholar
• Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998;7:75-83
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003;42(Suppl 3):iii23-31
   PubMed Web of Science ®Google Scholar
• van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011;60:1650-9
   PubMed Web of Science ®Google Scholar
• Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterol 2005;129:1171-8
   PubMed Web of Science ®Google Scholar
• Gill JM, Mainous AG 3rd, Koopman RJ, et al. Impact of EHR-based clinical decision support on adherence to guidelines for patients on NSAIDs: a randomized controlled trial. Ann Fam Med 2011;9:22-30
   PubMed Web of Science ®Google Scholar
• Tam LM, Fonarow GC, Bhatt DL, et al. Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: results from the Get With The Guidelines–Coronary Artery Disease Program. Circ Cardiovasc Qual Outcomes 2013;6:58-65
   PubMed Web of Science ®Google Scholar
• Lanas A, Polo-Tomas M, Roncales P, et al. Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. Am J Gastroenterol 2012;107:707-14
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337-45
   PubMed Web of Science ®Google Scholar
• Albeldawi M, Qadeer MA, Vargo JJ. Managing acute upper GI bleeding, preventing recurrences. Cleve Clin J Med 2010;77:131-42
   PubMed Web of Science ®Google Scholar
• Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13
   PubMed Web of Science ®Google Scholar
• Lewis JD, Bilker WB, Brensinger C, et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002;97:2540-9
   PubMed Web of Science ®Google Scholar
• Viviane A, Alan BN. Estimates of costs of hospital stay for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health 2008;11:1-3
   PubMed Web of Science ®Google Scholar
• Yavorski RT, Wong RK, Maydonovitch C, et al. Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities. Am J Gastroenterol 1995;90:568-73
   PubMed Web of Science ®Google Scholar
• Parker DR, Luo X, Jalbert JJ, et al. Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review. J Med Econ 2011;14:279-87
   PubMedGoogle Scholar
• O'Carroll R, Whittaker J, Hamilton B, et al. Predictors of adherence to secondary preventive medication in stroke patients. Ann Behav Med 2011;41:383-90
   PubMed Web of Science ®Google Scholar
• Moberg C, Naesdal J, Svedberg LE, et al. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. The Patient 2011;4:103-13
   PubMedGoogle Scholar
• Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15
   PubMed Web of Science ®Google Scholar
• Deighton C, O'Mahony R, Tosh J, et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009;338:b702
   PubMed Web of Science ®Google Scholar
• Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002;23:S24-30, discussion S1-4
   PubMed Web of Science ®Google Scholar